Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures

​ Conditions: Focal Epilepsy

Interventions: Drug: 40 mg/day vormatrogine for 12 weeks; Drug: 30 mg/day vormatrogine for 12 weeks; Drug: 20 mg/day vormatrogine for 12 weeks; Drug: Placebo

Sponsors: Praxis Precision Medicines

Recruiting Conditions: Focal Epilepsy
Interventions: Drug: 40 mg/day vormatrogine for 12 weeks; Drug: 30 mg/day vormatrogine for 12 weeks; Drug: 20 mg/day vormatrogine for 12 weeks; Drug: Placebo
Sponsors: Praxis Precision Medicines
Recruiting